Cellectis SA (NAS:CLLS)
$ 1.56 0 (0%) Market Cap: 154.13 Mil Enterprise Value: -15.24 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 70/100

Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript

Jun 13, 2019 / 03:00PM GMT
Release Date Price: $15.7 (+2.75%)
Maryana Ilya Breitman
Goldman Sachs Group Inc., Research Division - Research Analyst

I'm Maryana Breitman. I am an analyst with Goldman Sachs. We're required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discuss. The disclosures relate to investment banking relationships, compensation received or 1% or more ownership. I am prepared to read aloud disclosures for any issuer upon request. However, these disclosures are available in our most recent reports, available to you as clients on our firm's portals. Disclosures and updates to those disclosures are also available by ticker on the public's -- on the firm's public website. Also, the views stated by non-Goldman Sachs personnel do not necessarily reflect those of Goldman Sachs.

Good morning. It is my pleasure to welcome Simon Harnest, Vice President of Corporate Strategy and Finance of Cellectis.

Simon Harnest;Maryana Ilya Breitman
Cellectis S.A. - VP of Corporate Strategy & Finance;

Thank you, Maryana.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot